Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective

Alan Talevi · 2015

Read Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective by Alan Talevi (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/openalex-w1808513053.txt.

Description

Alan Talevi wrote this perspective piece on drug design. It appeared in Frontiers in Pharmacology in September 2015. Talevi works at the National University of La Plata. Drugs that hit many targets drew growing interest, he notes. Such drugs may help in complex diseases, he writes.

They may also help where resistance limits single-target drugs. Reusing known drugs for new paired diseases is another gain. Talevi calls the multi-target idea a skeleton key approach. He weighs its promise against its design limits. A medicinal chemist's view guides the whole discussion. The piece maps both hope and caution for the field.

Catalog record

CREATORAlan Talevi
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEOpenAlex / Frontiers in Pharmacology

Source: https://doi.org/10.3389/fphar.2015.00205

Browse the full library · About the Tower of Babel